Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

ABSTRACT:

Importance

The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available.

Objective

To assess the long-term efficacy and safety of the Ritux 3 treatment regimen.

Design, setting, and participants

This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015.

Exposure

Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group.

Main outcomes and measures

The primary outcome was the 5- and 7-year disease-free survi

SUBMITTER: Tedbirt B 

PROVIDER: S-EPMC10809134 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature